Predictive Value of Early Improvement in Bipolar Depression Trials: A Post-hoc Pooled Analysis of Two 8-week Aripiprazole Studies
Absence of early improvement after 3 weeks of treatment reliably predicted non-response/non-remission at study endpoint with high sensitivity and NPV. In patients with <20% improvement after 21 days of aripiprazole monotherapy, treatment should be modified, as continued use is unlikely to result in response/remission. Clinical decision-making to optimize treatment course in bipolar I depression may be appropriate after as little as 2 weeks and certainly within the first 3 weeks of treatment.
Authors
- Stephen J. Ganocy (ORCID: https://orcid.org/0000-0002-0801-3151)
- E. Vester-Blokland
- Joseph R. Calabrese (ORCID: https://orcid.org/0000-0003-4647-8571)
- James M. Eudicone (ORCID: https://orcid.org/0000-0001-7020-2490)
- David E. Kemp (ORCID: https://orcid.org/0000-0003-2653-5663)
- Randall Owen
- Robert D. McQuade
- Berit X. Carlson
- Quynh-Van Tran
- R.N. Marcus
Institutions
- Otsuka (Japan) (JP)
- Bristol-Myers Squibb (Germany) (DE)
- Otsuka Pharmaceutical (Spain) (ES)
- Case Western Reserve University (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4288
- Citations
- 11
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00